MedTrace Logo

Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition

NCT01064271 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2010-02-08

No results posted yet for this study

Summary

A Single-dose, Randomized, two-Period, Cross over Study

Conditions

  • Healthy

Interventions

DRUG

Risperidone

Risperidone Tablets 1 mg

Sponsors & Collaborators

  • Dr. Reddy's Laboratories Limited

    lead INDUSTRY

Principal Investigators

  • Shirley Ann Kennedy, MD · Novum Pharmaceutical Research Services, 5900 Penn Avenue, Pittsburgh, PA 15206-3817

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2006-10-31
Completion
2006-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01064271 on ClinicalTrials.gov